Figure 3.
Fixed effect regression of individual cellular and plasma biomarkers. Patients with cGVHD were divided into groups based on days post-HCT of cGVHD onset and compared with time-matched controls. (A) Early-onset of cGVHD before 4 months post-HCT were compared with control biomarkers at day +100. (B) Mid-onset of cGVHD between 4 to 8 months post-HCT were compared with control biomarkers at 6 months post-HCT. (C) Late-onset of cGVHD between 8 and 12 months post-HCT were compared with control biomarkers at 12 months post-HCT. Dashed horizontal lines correspond to a nominal P value threshold of .05. Dashed vertical lines indicate the log10 of the lower and upper limits of the effect ratio criterion. Circled and labeled dots represent cell and plasma biomarkers that met our criteria in both the mixed effect and across all 3 time points in the fixed effect models. Details are presented in supplemental Table 6.

Fixed effect regression of individual cellular and plasma biomarkers. Patients with cGVHD were divided into groups based on days post-HCT of cGVHD onset and compared with time-matched controls. (A) Early-onset of cGVHD before 4 months post-HCT were compared with control biomarkers at day +100. (B) Mid-onset of cGVHD between 4 to 8 months post-HCT were compared with control biomarkers at 6 months post-HCT. (C) Late-onset of cGVHD between 8 and 12 months post-HCT were compared with control biomarkers at 12 months post-HCT. Dashed horizontal lines correspond to a nominal P value threshold of .05. Dashed vertical lines indicate the log10 of the lower and upper limits of the effect ratio criterion. Circled and labeled dots represent cell and plasma biomarkers that met our criteria in both the mixed effect and across all 3 time points in the fixed effect models. Details are presented in supplemental Table 6.

Close Modal

or Create an Account

Close Modal
Close Modal